Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab + paclitaxel versus placebo + paclitaxel in previously untreated advanced or metastatic triple-negative breast cancer
2016-004024-29Phase 3Completed
- Sponsor
- Roche
- Start
- May 2017
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in triple-negative breast cancer (TNBC) comparing Atezolizumab + paclitaxel with Placebo + paclitaxel (2 arms). Primary endpoints: Progression-free survival in the PD-L1-positive subpopulation and Progression-free survival in the intention-to-treat population. Started May 2017; status: completed.
02
Drugs
atezolizumabpaclitaxel
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on 2016-004024-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004024-29.